Yesterday, Needham & Co.'s Alan Carr reiterated a 'buy' rating on shares of Cara Therapeutics, Inc. (NASDAQ:CARA) alongside a price target of $23 per share. With an analyst average price target of $25 per share, Needham's price target is towards the low end of the five analysts we track that cover Cara. With a last trade price of $13.91 for shares of CARA, this price target represents approximately 65% potential upside.
Be sure to subscribe to one or more of our free e-mail newsletters so you never miss an important marijuana stock update. Also, don't forget to connect with The Daily Marijuana Observer on social media via Facebook, Twitter, StockTwits, YouTube, and Instagram.